Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.
Leuk Lymphoma
; 50(1): 92-100, 2009 Jan.
Article
em En
| MEDLINE
| ID: mdl-19172498
ABSTRACT
The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7 mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500 microL), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Equinocandinas
/
Lipopeptídeos
/
Doenças Hematológicas
/
Micoses
/
Antifúngicos
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article